Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Non-Current Liabilities (2022 - 2025)

Stoke Therapeutics has reported Total Non-Current Liabilities over the past 4 years, most recently at $8.1 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $8.1 million for Q4 2025, up 226.96% from a year ago — trailing twelve months through Dec 2025 was $8.1 million (up 226.96% YoY), and the annual figure for FY2025 was $8.1 million, up 226.96%.
  • Total Non-Current Liabilities for Q4 2025 was $8.1 million at Stoke Therapeutics, down from $10.4 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for STOK hit a ceiling of $53.1 million in Q1 2022 and a floor of $2.5 million in Q4 2024.
  • Median Total Non-Current Liabilities over the past 4 years was $32.8 million (2023), compared with a mean of $28.3 million.
  • Biggest five-year swings in Total Non-Current Liabilities: plummeted 93.47% in 2024 and later soared 226.96% in 2025.
  • Stoke Therapeutics' Total Non-Current Liabilities stood at $39.8 million in 2022, then fell by 4.69% to $38.0 million in 2023, then plummeted by 93.47% to $2.5 million in 2024, then soared by 226.96% to $8.1 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $8.1 million (Q4 2025), $10.4 million (Q3 2025), and $10.9 million (Q2 2025) per Business Quant data.